More Information Product Details Synonyms Product Type Properties Clone Isotype Immunogen/Antigen Application Crossreactivity Specificity Purity Purity Detail Formulation Reconstitution Shipping and Handling Shipping Short Term Storage Long Term Storage Handling Advice Use/Stability Documents MSDS Product Specification Sheet Datasheet

Vascular Endothelial Growth Factor Receptor-2; KDR; FLK-1

Monoclonal Antibody

3(4H3)

Mouse IgG1

Recombinant human soluble extracellular VEGFR-2.

Flow Cytometry: (2-5μg/ml)Western Blot: (2-5μg/ml)Optimal conditions must be determined individually for each application.

Human

The antibody will detect native human VEGFR-2/KDR in ELISA experiments and on the surface of different human cell types.

Protein G purified.

Protein G purified.

Lyophilized.

Centrifuge vial prior to opening. Reconstitute with sterile water to a concentration of 0.1-1.0mg/ml.

BLUE ICE

+4°C

-20°C

After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.

Stable for at least 6 months after receipt when stored at -20°C.

Download PDF

Download PDF

Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.

Product References

Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization: G. Nowak, et al.; Circulation 110, 3699 (2004)

>>> 更多资讯详情请访问蚂蚁淘商城